Effects of Pulmonary Rehabilitation on Functional & Health Status Measures

Status Completed

Clinical Trial Summary

Clinical Trial Description

The inclusion of Pulmonary Rehabilitation (PR) as part of the management of pulmonary fibrosis although being highly recommended and recommended in guidelines still sees studies exploring the outcomes from such an intervention limited. The present study aims to contribute to the available literature by investigating the effects of a high intensity, 12week PR programme on functional and quality of life measures in patients with a diagnosis of pulmonary fibrosis. This study reports outcomes of an observational, quasi experimental type of study. A total of 120 participants were recruited: 60 patients formed part of the active group, another 60 patients were enrolled in an inactive group. Each participant was classified according to the modified Medical Research Council dyspnoea scale and placed in one of 5 categories (0 to 4) according to self-perceived breathlessness during daily activities. The following outcomes were measured: Lung function tests including plethysmography and diffusion capacity of carbon monoxide (DLCO), functional tests (6-minute walking test, Dyspnoea Borg Scale) and Health status measures (St George's Respiratory Questionnaire and HAD score). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03542318
Study type	Observational
Source	University of Malta
Contact
Status	Completed
Phase
Start date	March 1, 2014
Completion date	January 31, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04638517` - The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis	Phase 2
Recruiting	`NCT05299333` - Comparison of Pulmonary Telerehabilitation and Physical Activity Recommendations in Patients With Post Covid Fibrosis	N/A
Terminated	`NCT04119115` - Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Not yet recruiting	`NCT05890573` - Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19	N/A
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT01417156` - Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)	Phase 2
Terminated	`NCT00981747` - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis	Phase 2/Phase 3
Completed	`NCT00001596` - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome	Phase 2
Completed	`NCT00052052` - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2
Completed	`NCT01442779` - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis	Phase 2
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Recruiting	`NCT00001532` - Role of Genetic Factors in the Development of Lung Disease
Recruiting	`NCT04767074` - A Non-pharmacological Cough Control Therapy	N/A
Recruiting	`NCT04864990` - Dyspnea and Idiopathic Pulmonary Fibrosis
Completed	`NCT01961362` - Supplemental Oxygen in Pulmonary Fibrosis
Completed	`NCT01271842` - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study	N/A
Completed	`NCT00650091` - Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF	Phase 3
Active, not recruiting	`NCT00258544` - Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
Enrolling by invitation	`NCT04930289` - Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Completed	`NCT02055222` - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease

Effects of Pulmonary Rehabilitation on Functional and Health Status Measures in Pulmonary Fibrosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms